DE602004031988D1 - Antikörper gegen insulinartigen Wachstumsfaktor-I-Rezeptor und deren Verwendung - Google Patents

Antikörper gegen insulinartigen Wachstumsfaktor-I-Rezeptor und deren Verwendung

Info

Publication number
DE602004031988D1
DE602004031988D1 DE602004031988T DE602004031988T DE602004031988D1 DE 602004031988 D1 DE602004031988 D1 DE 602004031988D1 DE 602004031988 T DE602004031988 T DE 602004031988T DE 602004031988 T DE602004031988 T DE 602004031988T DE 602004031988 D1 DE602004031988 D1 DE 602004031988D1
Authority
DE
Germany
Prior art keywords
receptor
growth factor
antibodies against
against insulin
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004031988T
Other languages
English (en)
Inventor
Yvo Graus
Erhard Kopetzki
Klaus-Peter Kuenkele
Olaf Mundigl
Paul Parren
Frank Rebers
Ralf Schumacher
De Winkel Jan Van
Vugt Martine Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602004031988D1 publication Critical patent/DE602004031988D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE602004031988T 2003-07-10 2004-07-09 Antikörper gegen insulinartigen Wachstumsfaktor-I-Rezeptor und deren Verwendung Expired - Lifetime DE602004031988D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03015526 2003-07-10

Publications (1)

Publication Number Publication Date
DE602004031988D1 true DE602004031988D1 (de) 2011-05-05

Family

ID=33560758

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602004031988T Expired - Lifetime DE602004031988D1 (de) 2003-07-10 2004-07-09 Antikörper gegen insulinartigen Wachstumsfaktor-I-Rezeptor und deren Verwendung
DE602004017614T Expired - Lifetime DE602004017614D1 (de) 2003-07-10 2004-07-09 Antikörper gegen den insulinähnlichen wachstumfaktor-i-rezeptor und verwendungen dafür

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE602004017614T Expired - Lifetime DE602004017614D1 (de) 2003-07-10 2004-07-09 Antikörper gegen den insulinähnlichen wachstumfaktor-i-rezeptor und verwendungen dafür

Country Status (29)

Country Link
US (3) US7579157B2 (de)
EP (4) EP1646720B1 (de)
JP (2) JP4276262B2 (de)
KR (1) KR100795745B1 (de)
CN (1) CN100453645C (de)
AR (1) AR046071A1 (de)
AT (2) ATE502959T1 (de)
AU (3) AU2004256215B2 (de)
BR (1) BRPI0412478B8 (de)
CA (1) CA2532173C (de)
CO (1) CO5640053A1 (de)
CY (1) CY1116227T1 (de)
DE (2) DE602004031988D1 (de)
DK (3) DK2272873T3 (de)
ES (3) ES2360454T3 (de)
HK (1) HK1094713A1 (de)
IL (1) IL172925A (de)
MX (1) MXPA06000270A (de)
MY (1) MY140209A (de)
NO (2) NO339935B1 (de)
NZ (1) NZ544455A (de)
PL (3) PL1959014T3 (de)
PT (3) PT2272873E (de)
RU (2) RU2363706C2 (de)
SG (1) SG129437A1 (de)
SI (1) SI2272873T1 (de)
TW (1) TWI290147B (de)
WO (1) WO2005005635A2 (de)
ZA (1) ZA200600181B (de)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101086533B1 (ko) * 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
EP1622942B1 (de) * 2003-05-01 2014-11-19 ImClone LLC Komplett menschliche antikörper gegen den rezeptor des insulin-ähnlichen wachstumsfaktor i
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
WO2005047512A2 (en) 2003-11-12 2005-05-26 Shering Corporation Plasmid system for multigene expression
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
EP2322217A3 (de) 2004-07-16 2011-09-28 Pfizer Products Inc. Kombinationsbehandlung für nicht-hämatologische bösartige Erkrankungen mit einem anti-IGF-1R-Antikörper
WO2006060419A2 (en) * 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
CN101222926B (zh) * 2005-04-15 2013-07-17 默沙东公司 用于治疗或预防癌症的方法和组合物
NZ564098A (en) * 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
SI2100614T1 (sl) 2005-06-17 2014-03-31 Imclone Llc PROTITELO PROTI PDGFR-alfa ZA UPORABO PRI ZDRAVLJENJU TUMORJEV
WO2007000328A1 (en) * 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
TW200732472A (en) * 2005-10-21 2007-09-01 Hoffmann La Roche Method for the recombinant expression of a polypeptide
CN101341252B (zh) 2005-10-28 2011-08-17 弗·哈夫曼-拉罗切有限公司 啮齿动物细胞中的蛋白质表达
EA017265B1 (ru) * 2006-02-03 2012-11-30 Имклоун Элэлси Применение антитела imc-a12, которое является ингибитором igf-ir, для лечения рака предстательной железы
KR101402592B1 (ko) * 2006-03-06 2014-06-17 에스케이바이오팜 주식회사 피록시캄-무기물 복합체를 포함하는 경피투여 조성물 및이를 이용한 패치시스템
JP4902674B2 (ja) 2006-03-09 2012-03-21 エフ．ホフマン−ラ ロシュ アーゲー 抗薬物抗体アッセイ法
KR20080104160A (ko) * 2006-03-28 2008-12-01 에프. 호프만-라 로슈 아게 항-ｉｇｆ-１ｒ 인간 단일클론 항체 제형
MX2008012146A (es) * 2006-03-28 2008-10-03 Biogen Idec Inc Anticuerpos anti-receptor 1 de factor de crecimiento tipo insulina (igf-1r) y uso de los mismos.
CN101460522B (zh) * 2006-04-11 2014-07-23 弗·哈夫曼-拉罗切有限公司 糖基化抗体
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
JP4964957B2 (ja) 2006-09-12 2012-07-04 エフ．ホフマン−ラ ロシュ アーゲー 抗薬物抗体アッセイ
MX2009005466A (es) 2006-11-22 2009-08-17 Adnexus A Bristol Myers Sqibb Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
US20090068110A1 (en) * 2006-12-22 2009-03-12 Genentech, Inc. Antibodies to insulin-like growth factor receptor
US20080226635A1 (en) * 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
CA2677901A1 (en) 2007-02-27 2008-09-04 F. Hoffmann-La Roche Ag Method for the assessment of the inhibitory activity of antibodies against insulin-like growth factor i receptor
JP2010520204A (ja) * 2007-03-02 2010-06-10 アムジェン インコーポレイテッド 腫瘍疾患を治療するための方法および組成物
MX2009010179A (es) * 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
BRPI0810710A2 (pt) 2007-05-02 2014-10-21 Hoffmann La Roche Método para estabilização de uma proteína.
WO2008144345A2 (en) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
LT2167540T (lt) * 2007-06-29 2018-04-25 F. Hoffmann-La Roche Ag Sunkioji grandinė mutantė, pagerinanti imunoglobulino gamybą
CA2697922A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
JP2010537985A (ja) * 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド 抗ｉｇｆ−１ｒ抗体およびその使用
US20110097318A1 (en) * 2007-08-31 2011-04-28 Amgen Inc. Solid-State Protein Formulation
EP2205280B1 (de) * 2007-09-27 2019-09-04 Amgen Inc. Pharmazeutische formulierungen
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
CA2709127C (en) 2007-12-15 2013-11-12 F. Hoffmann-La Roche Ag Distinguishing assay
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP2247615B1 (de) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Zielgerichtete therapeutika auf der basis von egfr gentechnisch hergestellten proteinen
EP2799448A1 (de) 2008-05-22 2014-11-05 Bristol-Myers Squibb Company Polyvalente Proteine mit Fibronectin-Gerüstdomänen
BRPI0919382A2 (pt) * 2008-09-26 2016-01-05 Roche Glycart Ag anticorpos bi-específicos anti-egfr/anti-igf-1r
KR101827332B1 (ko) 2008-12-12 2018-02-09 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｇｆ 항체
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
CA2749354A1 (en) 2009-03-30 2010-10-14 F. Hoffmann-La Roche Ag A method for avoiding glass fogging
AR075982A1 (es) 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
EP2236139A1 (de) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Kombinationstherapie aus Erlotinib mit einem Anti-IGF-1R-Antikörper, der die Bindung von Insulin an den Insulinrezeptor nicht hemmt
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
CA2757931C (en) 2009-04-07 2019-03-26 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
WO2011034605A2 (en) 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
BR112012005668A2 (pt) 2009-10-19 2020-10-13 F. Hoffmann La Roche Ag '' linhagem celular, anticorpo, uso de um anticorpo, kit, método de detecção de um anticorpo terapêutico, método de determinação imunológica de um anticorpo terapêutico, composição de anticorpo, uso de uma composição de anticorpo''
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
KR102223417B1 (ko) 2009-10-26 2021-03-05 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
US20120220594A1 (en) 2009-10-30 2012-08-30 Bristol-Meyers Squibb Company Methods for treating cancer in patients having igf-1r inhibitor resistance
WO2011083391A2 (en) 2010-01-05 2011-07-14 Pfizer Inc. Biomarkers for anti-igf-ir cancer therapy
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
DK2564202T3 (en) 2010-04-29 2015-10-05 Theradiag Sa A method for detecting anti-drug antibodies
ES2545411T5 (es) 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
CA2804185C (en) 2010-07-12 2017-03-21 Covx Technologies Ireland Limited Multifunctional antibody conjugates
JP2013541937A (ja) * 2010-08-05 2013-11-21 エフ．ホフマン−ラ ロシュ アーゲー 抗ｍｈｃ抗体−抗ウイルス性サイトカイン融合タンパク質
MX360347B (es) 2010-08-17 2018-10-30 F Hoffmann La Roche Ag Star Anticuerpo anti-inmunoglobulina g1 humana.
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CA2825894C (en) 2011-02-02 2021-11-30 Amgen Inc. Prognosis of cancer using a circulating biomarker
KR20130118941A (ko) 2011-02-10 2013-10-30 로슈 글리카트 아게 면역치료법
CA2825081A1 (en) 2011-02-28 2012-09-07 Birgit Bossenmaier Antigen binding proteins
WO2012116927A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
WO2012135315A1 (en) 2011-03-31 2012-10-04 Amgen Inc. Vial adapter and system
CA3145238A1 (en) 2011-04-20 2012-10-26 Amgen Inc. Autoinjector apparatus
RU2013150331A (ru) 2011-04-20 2015-05-27 Рош Гликарт Аг СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
KR101684750B1 (ko) 2011-09-23 2016-12-08 로슈 글리카트 아게 이중특이적 항-egfr/항-igf-1r 항체
US20140309229A1 (en) 2011-10-13 2014-10-16 Bristol-Myers Squibb Company Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
ES2923766T3 (es) 2011-10-14 2022-09-30 Amgen Inc Inyector y método de montaje
AU2012335541B2 (en) 2011-11-11 2017-07-06 Duke University Combination drug therapy for the treatment of solid tumors
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
CA2871880A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
MX2014014804A (es) 2012-06-27 2015-02-12 Hoffmann La Roche Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo.
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
ES2848732T3 (es) 2012-08-07 2021-08-11 Roche Glycart Ag Inmunoterapia mejorada
EP2727941A1 (de) 2012-11-05 2014-05-07 MAB Discovery GmbH Verfahren zur Herstellung multispezifischer Antikörper
EP2914629A1 (de) 2012-11-05 2015-09-09 MAB Discovery GmbH Verfahren zur herstellung multispezifischer antikörper
CA2884887C (en) 2012-11-21 2023-09-12 Amgen Inc. Drug delivery device including insertion member and reservoir
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
EP2968775B1 (de) 2013-03-15 2019-12-18 Amgen Inc. Medikamentenkassette, autoinjektor und autoinjektorsystem
JP6670740B2 (ja) 2013-03-22 2020-03-25 アムジエン・インコーポレーテツド 注入器および組み立て法
PE20151925A1 (es) 2013-04-29 2015-12-26 Hoffmann La Roche Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares
SG10201800492PA (en) 2013-04-29 2018-03-28 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
CN105378480B (zh) 2013-07-04 2018-06-12 豪夫迈·罗氏有限公司 检测血清样品中抗药物抗体的干扰抑制性免疫测定
MX2016003593A (es) 2013-10-11 2016-06-02 Hoffmann La Roche Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
JP7086520B2 (ja) 2013-10-24 2022-06-20 アムジエン・インコーポレーテツド インジェクター及び組み立ての方法
CA3168888A1 (en) 2013-10-24 2015-04-30 Amgen Inc. Drug delivery system with temperature-sensitive control
EP3094648A1 (de) 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region-varianten mit verbesserter protein-a-bindung
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
EP3785749A1 (de) 2014-05-07 2021-03-03 Amgen Inc. Autoinjektor mit stossabsorbierenden elementen
SG11201609963PA (en) 2014-06-03 2016-12-29 Amgen Inc Devices and methods for assisting a user of a drug delivery device
CA2957960C (en) 2014-10-14 2023-08-22 Amgen, Inc. Drug injection device with visual and audible indicators
EP3227332B1 (de) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispezifische antikörper
EP3848072A1 (de) 2014-12-19 2021-07-14 Amgen Inc. Medikamentenabgabevorrichtung mit näherungssensor
JP2017538512A (ja) 2014-12-19 2017-12-28 アムジエン・インコーポレーテツド ライブボタンまたはユーザインタフェースフィールドを含む薬物送達装置
US10583245B2 (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
US11806509B2 (en) 2015-02-27 2023-11-07 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
EP4035711A1 (de) 2016-03-15 2022-08-03 Amgen Inc. Verringerung der wahrscheinlichkeit auf glasbruch in arzneimittelabgabevorrichtungen
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
EP3458988B1 (de) 2016-05-16 2023-10-18 Amgen Inc. Datenverschlüsselung in medizinischen vorrichtungen mit eingeschränkter rechenfähigkeit
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
EP3478342A1 (de) 2016-07-01 2019-05-08 Amgen Inc. Arzneimittelabgabevorrichtung mit minimiertem teilebruchrisiko nach aufprallereignissen
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
CA3049780A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
EP3582829A1 (de) 2017-02-17 2019-12-25 Amgen Inc. Einführmechanismus für eine arzneimittelabgabevorrichtung
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
AU2018231107B2 (en) 2017-03-06 2023-04-20 Amgen Inc. Drug delivery device with activation prevention feature
SG11201908058UA (en) 2017-03-07 2019-09-27 Amgen Inc Needle insertion by overpressure
WO2018165499A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
CN114588404B (zh) 2017-03-28 2024-07-09 美国安进公司 柱塞杆和注射器组件系统以及方法
JP7200134B2 (ja) 2017-06-08 2023-01-06 アムジエン・インコーポレーテツド トルク駆動式薬物送達デバイス
EP3634539A1 (de) 2017-06-08 2020-04-15 Amgen Inc. Spritzenanordnung für eine wirkstofffreisetzungsvorrichtung und verfahren zur montage
AU2018288604B2 (en) 2017-06-22 2023-12-21 Amgen Inc. Device activation impact/shock reduction
EP3641861A1 (de) 2017-06-23 2020-04-29 Amgen Inc. Elektronische arzneimittelabgabevorrichtung mit einer durch eine schaltungsanordnung aktivierten kappe
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
WO2019018169A1 (en) 2017-07-21 2019-01-24 Amgen Inc. PERMEABLE GAS SEALING ELEMENT FOR MEDICINE CONTAINER AND METHODS OF ASSEMBLY
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
EP3658203B1 (de) 2017-07-25 2022-08-31 Amgen Inc. Arzneimittelabgabevorrichtung mit getriebemodul und verwandtes verfahren zur montage
EP3664863A2 (de) 2017-08-09 2020-06-17 Amgen Inc. Hydraulisch-pneumatisches druckkammer-arzneimittelabgabesystem
MA49897A (fr) 2017-08-18 2020-06-24 Amgen Inc Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
WO2019070472A1 (en) 2017-10-04 2019-04-11 Amgen Inc. FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
EP4257164A3 (de) 2017-10-06 2024-01-17 Amgen Inc. Arzneimittelabgabevorrichtung mit verriegelungsvorrichtung und zugehöriges montageverfahren
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
WO2019090086A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Systems and approaches for sterilizing a drug delivery device
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
MA50553A (fr) 2017-11-06 2020-09-16 Amgen Inc Dispositif d'administration de médicament avec détection de positionnement et de débit
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
AU2018368338B2 (en) 2017-11-16 2024-07-25 Amgen Inc. Autoinjector with stall and end point detection
JP7370969B2 (ja) 2017-11-16 2023-10-30 アムジエン・インコーポレーテツド 薬物送達デバイスの扉ラッチ機構
US11208489B2 (en) 2018-01-24 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
WO2019173352A1 (en) 2018-03-05 2019-09-12 Hznp Limited Methods for the treatment of thyroid eye disease
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
EP3826701A1 (de) 2018-07-24 2021-06-02 Amgen Inc. Ausgabevorrichtung zur verabreichung von arzneimitteln
WO2020023451A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
US20210260279A1 (en) 2018-07-24 2021-08-26 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
EP3829692A1 (de) 2018-07-31 2021-06-09 Amgen Inc. Flüssigkeitsweganordnungen für wirkstofffreisetzungsvorrichtung
WO2020068623A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
WO2020068476A1 (en) 2018-09-28 2020-04-02 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
SG11202103236YA (en) 2018-10-02 2021-04-29 Amgen Inc Injection systems for drug delivery with internal force transmission
AU2019355979A1 (en) 2018-10-05 2021-03-18 Amgen Inc. Drug delivery device having dose indicator
EP3866890A1 (de) 2018-10-15 2021-08-25 Amgen Inc. Medikamentenabgabevorrichtung mit dämpfungsmechanismus
SG11202101824VA (en) 2018-10-15 2021-03-30 Amgen Inc Platform assembly process for drug delivery device
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
AU2019370159A1 (en) 2018-11-01 2021-04-22 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
WO2020219482A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
CA3148261A1 (en) 2019-08-23 2021-03-04 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
KR20220151619A (ko) * 2020-02-04 2022-11-15 호라이즌 테라퓨틱스 아일랜드 디에이씨 피부경화증 및 관련된 병태의 치료 방법
KR20240011135A (ko) 2021-05-21 2024-01-25 암젠 인크 약물 용기를 위한 충전 레시피를 최적화하는 방법
KR20240117639A (ko) * 2021-12-23 2024-08-01 비리디안 쎄라퓨틱스, 인크. 갑상선 눈 질환의 치료를 위한 조성물 및 방법
AU2023205804A1 (en) 2022-01-09 2024-07-25 Kriya Therapeutics, Inc. Vector constructs for delivery of nucleic acids encoding therapeutic anti-igf-1r antibodies and methods of using the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
EP0730740B1 (de) 1993-11-23 1998-02-11 Genentech, Inc. Kinaserezeptoraktivierungstest
US6417330B1 (en) * 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
PL217921B1 (pl) 2001-01-05 2014-09-30 Amgen Fremont Inc Przeciwciało przeciw receptorowi insulinopodobnego czynnika wzrostu I, zawierająca go kompozycja farmaceutyczna, sposób jego wytwarzania, zastosowania, linia komórkowa, wyizolowana cząsteczka kwasu nukleinowego, wektor, komórka gospodarza oraz zwierzę transgeniczne
AR035885A1 (es) * 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
WO2003059951A2 (fr) 2002-01-18 2003-07-24 Pierre Fabre Medicament Anticorps anti-igf-ir et leurs applications
KR101086533B1 (ko) 2002-05-24 2011-11-23 쉐링 코포레이션 중화 사람 항-ｉｇｆｒ 항체, 이를 제조하는 방법 및 이를 포함하는 조성물
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
JP2006517581A (ja) 2003-02-13 2006-07-27 ファイザー・プロダクツ・インク 抗インスリン様増殖因子ｉ受容体抗体の使用
MXPA05009837A (es) * 2003-03-14 2005-12-05 Pharmacia Corp Anticuerpos para el receptor del factor de crecimiento tipo insulina-i, para el tratamiento de canceres.
EP1622942B1 (de) * 2003-05-01 2014-11-19 ImClone LLC Komplett menschliche antikörper gegen den rezeptor des insulin-ähnlichen wachstumsfaktor i
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR

Also Published As

Publication number Publication date
US7572897B2 (en) 2009-08-11
HK1094713A1 (en) 2007-04-04
AR046071A1 (es) 2005-11-23
PT1959014E (pt) 2011-06-15
EP2243835A3 (de) 2010-11-10
TWI290147B (en) 2007-11-21
US20050008642A1 (en) 2005-01-13
EP1959014B1 (de) 2011-03-23
KR100795745B1 (ko) 2008-01-17
JP2008538273A (ja) 2008-10-23
NO20056246L (no) 2006-02-09
ATE502959T1 (de) 2011-04-15
EP2243835A2 (de) 2010-10-27
JP4464450B2 (ja) 2010-05-19
PL1646720T3 (pl) 2009-04-30
ES2317020T3 (es) 2009-04-16
WO2005005635A2 (en) 2005-01-20
PL1959014T3 (pl) 2011-08-31
CA2532173C (en) 2013-11-12
DK2272873T3 (en) 2015-03-09
CO5640053A1 (es) 2006-05-31
MY140209A (en) 2009-11-30
EP2272873B1 (de) 2015-01-28
EP1959014A3 (de) 2009-01-14
AU2004256215B2 (en) 2008-07-17
EP2272873A2 (de) 2011-01-12
KR20060054296A (ko) 2006-05-22
DK1959014T3 (da) 2011-04-18
AU2004256215A1 (en) 2005-01-20
JP2009077709A (ja) 2009-04-16
EP1646720A2 (de) 2006-04-19
DE602004017614D1 (de) 2008-12-18
US7579157B2 (en) 2009-08-25
AU2008202949A1 (en) 2008-07-31
BRPI0412478B1 (pt) 2020-04-14
DK1959014T5 (da) 2011-06-06
PT1646720E (pt) 2008-12-26
DK1646720T3 (da) 2009-01-05
NO340438B1 (no) 2017-04-24
JP4276262B2 (ja) 2009-06-10
ZA200600181B (en) 2007-04-25
SI2272873T1 (sl) 2015-05-29
TW200513469A (en) 2005-04-16
CY1116227T1 (el) 2017-02-08
EP2272873A3 (de) 2011-09-28
US20080132686A1 (en) 2008-06-05
ES2360454T9 (es) 2012-02-16
RU2006103854A (ru) 2007-08-20
IL172925A (en) 2013-07-31
PT2272873E (pt) 2015-04-07
NO20161389A1 (no) 2016-09-02
RU2363706C2 (ru) 2009-08-10
BRPI0412478B8 (pt) 2021-05-25
AU2008202949B2 (en) 2008-09-25
CN100453645C (zh) 2009-01-21
AU2008207635B2 (en) 2008-11-20
EP1959014B9 (de) 2011-12-28
ATE413454T1 (de) 2008-11-15
AU2008207635A1 (en) 2008-09-25
BRPI0412478A (pt) 2006-09-19
ES2360454T3 (es) 2011-06-06
IL172925A0 (en) 2006-06-11
SG129437A1 (en) 2007-02-26
NZ544455A (en) 2008-12-24
MXPA06000270A (es) 2006-04-07
NO339935B1 (no) 2017-02-20
RU2008126743A (ru) 2010-01-10
EP1959014A2 (de) 2008-08-20
US20090275126A1 (en) 2009-11-05
ES2534638T3 (es) 2015-04-27
CN1823163A (zh) 2006-08-23
WO2005005635A3 (en) 2005-08-25
PL2272873T3 (pl) 2015-06-30
EP1646720B1 (de) 2008-11-05
CA2532173A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
DE602004031988D1 (de) Antikörper gegen insulinartigen Wachstumsfaktor-I-Rezeptor und deren Verwendung
ATE435872T1 (de) Anti-interleukin-1 rezeptor antikörper und deren verwendung
ATE456581T1 (de) Antikörper gegen il21-rezeptor und deren verwendung
ATE446953T1 (de) P2x7-rezeptorantagonisten und deren verwendung
ATE464322T1 (de) Antikörper gegen den rezeptor für den insulinähnlichen wachstumsfaktor i
DE602005023639D1 (de) Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten
ATE370128T1 (de) Benzotriazol-1-ylaminoacetonitril-verbindungen und deren verwendung zur schädlingsbekämpfung
DE602005003186D1 (de) Fluorkopolymer und dessen Verwendung
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
ATE412013T1 (de) Anti-osteopontin-antikörper und dessen verwendung
DE60328087D1 (de) Aryl substituierte pyrimidine und deren verwendung
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
DE602005011593D1 (de) Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten
ATE396185T1 (de) Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten
DE602005009988D1 (de) Härtbare Zusammensetzung und deren Verwendung
DE602004027354D1 (de) SUBSTITUIERTE 8y-PYRIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ON- UND 8y-PYRIMIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ONDERIVATE UND DEREN VERWENDUNG BEI NEURODEGENERATIVEN KRANKHEITEN
ATE418543T1 (de) Substituierte 1,4-dipiperidin-4-yl- piperazinderivate und deren verwendung als neurokininantagonisten
ATE500242T1 (de) Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl- piperazinderivate und deren verwendung als neurokinin antagonisten
DE602004028700D1 (de) Kosmetische Zusammensetzungen und deren Verwendung
ATE555097T1 (de) 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente
DE602005007866D1 (de) 1-phenyl- und 1-pyridylpyrazolderivate und deren verwendung als pestizide
DE602006008025D1 (de) Amidverbindungen und deren verwendung
DE602004022169D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ATA4472003A (de) R-hydroxynitrillyasen mit verbesserter substratakzeptanz und deren verwendung
DE60328713D1 (de) Blockcopolymer-modifizierte bitumenpappen und deren verwendung